Orla McNally

Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy.

Paul A Cohen, Yee Leung, Lyndal Anderson, Rachael van der Griend, Paola Chivers, Sanela Bilic, Sophie Bittinger, Alison Brand, Max K Bulsara, Jim Codde, Lois Eva, Louise Farrell, Dianne Harker, Unine Herbst, Stephanie Jeffares, Diane Loh, Orla McNally, Ganendra Raj Mohan, Tarryn Nicholson, Aime Powell, et al.

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVE: Adenocarcinoma in situ (AIS) of the cervix is a precursor to cervical adenocarcinoma. When AIS is detected by cervical ..

Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.

Charles H Norell, John Butler, Rhonda Farrell, Alon Altman, James Bentley, Citadel J Cabasag, Paul A Cohen, Scott Fegan, Michael Fung-Kee-Fung, Charlie Gourley, Neville F Hacker, Louise Hanna, Claus Kim Høgdall, Gunnar Kristensen, Janice Kwon, Orla McNally, Gregg Nelson, Andy Nordin, Dearbhaile O'Donnell, Tine Schnack, et al.

Journal article  |  2020  |  International Journal of Gynecologic Cancer

INTRODUCTION: The International Cancer Benchmarking Partnership demonstrated international differences in ovarian cancer survival,..

Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care

Luke McLean, James R Whittle, Jonathan Graham, Huda Ismail, Meir Lichtenstein, Rodney J Hicks, Orla McNally, Alan Herschtal, Mark Rosenthal, Danny Rischin, Anne Hamilton

Journal article  |  2020  |  Gynecologic Oncology

BACKGROUND: Glomerular filtration rate (GFR) measured by Chromium-51-EDTA excretion (51Cr-GFR) is considered the gold standard of ..

Therapeutic options for mucinous ovarian carcinoma

Kylie L Gorringe, Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, David DL Bowtell, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Sian Fereday, C Blake Gilks, Charlie Gourley, Alison M Hadley, Joy Hendley, Sally M Hunter, Scott H Kaufmann, et al.

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVE: Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemother..

The molecular origin and taxonomy of mucinous ovarian carcinoma

Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, Michael S Anglesio, George Au-Yeung, Maret Bohm, David Dl Bowtell, Alison Brand, Georgia Chenevix-Trench, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Renee Demeo, Rhiannon Dudley, Nicole Fairweather, et al.

Journal article  |  2019  |  NATURE COMMUNICATIONS

Surgically Managed Ovarian Masses at the Royal Children's Hospital, Melbourne-19 Year Experience

JA How, JL Marino, SR Grover, Y Heloury, M Sullivan, A Mellor, O McNally, Y Jayasinghe

Journal article  |  2019  |  Journal of Pediatric Surgery

BACKGROUND/PURPOSE: To describe the clinicopathological characteristics and management of surgically removed ovarian masses at the..

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Monica Tang, Rachel L O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander

Journal article  |  2019  |  Gynecologic Oncology

OBJECTIVE: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borde..

Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study

Olga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, Leakhena Leas, Tiffany Boughtwood, Kathryn Alsop, Giada Zapparoli, Alexander Dobrovic, Yi-An Ko, Arthur L Hsu, Clare J Love, Sebastian Lunke, Matthew J Wakefield, Orla McNally, Michael Quinn, Sumitra Ananda, Deborah Neesham, Anne Hamilton, Marisa Grossi, Alison Freimund, et al.

Journal article  |  2019  |  JCO Precision Oncology

Pathological process has a crucial role in sentinel node biopsy for vulvar cancer

Peter Sykes, Lois Eva, Rachael van der Griend, Orla McNally, Penelope Blomfield, Alison Brand, Amanda Tristram, Cecile Bergzoll, Simone Petrich, Diane Kenwright, Kathryn Payne, Mayada Kellow, Carrie Innes, Dianne Harker, Lewis Perrin, Paul Cohen, Ken Jaaback, Bryony Simcock

Journal article  |  2019  |  Gynecologic Oncology

SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models

GY Ho, H Barker, C Vanderberg, O Kondrashova, E Kyran, E Lieschke, O McNally, A Hamilton, V Heong, R Hansen, S Milutinovic, B Strouse, M Hedrick, C Hassig, D Bowtell, W Matthew, C Scott

Conference Proceedings  |  2018  |  EUROPEAN JOURNAL OF CANCER